Transcriptomics: Point Of Departure, Mode of Action, and Similarity
Translate gene-expression responses into evidence that clarifies dose, biological pathways, mode of action, and biological similarity.
Transcriptomics provides an early, biology-based view of how a compound is affecting cells and which responses may warrant closer investigation. As part of a tiered approach, it can help identify points of departure, reveal biological pathways and potential modes of action, and determine whether compounds behave similarly enough to support grouping or read-across.
ScitoVation combines transcriptomics, benchmark-dose analysis, pathway interpretation, and biological similarity methods to translate gene-expression responses into evidence that supports compound prioritization, human-relevance assessment, and clearer safety decisions.
Why ScitoVation?
ScitoVation combines scientific consulting with ScitoSim to connect transcriptomic analysis with the wider toxicological evidence and decision it needs to support.
We recommend transcriptomics as an early component of a tiered strategy where biological-response data can help determine what needs further investigation and where additional testing is most likely to add value.
Decision-led analysis: Start with the safety question, then select the transcriptomic analysis and level of interpretation appropriate to the decision.
Biology in context: Interpret gene-expression responses alongside dose, pathways, traditional endpoints, and other available evidence rather than treating transcriptomic signals in isolation.
Expert judgment and transparent methods: Keep analytical choices, benchmark-dose results, pathways, and interpretation visible so the scientific reasoning can be reviewed and communicated.
From signal to next step: Use transcriptomic evidence to identify points of departure, test mode-of-action hypotheses, assess biological similarity, and determine where further investigation is needed.
How We Use Transcriptomics to Identify Points of Departure
ScitoVation uses transcriptomic data and benchmark-dose modeling to estimate the dose associated with defined gene-expression and pathway responses.
Combining transcriptomic responses with pathway analysis and traditional endpoints, we help clients establish scientifically supported points of departure for risk assessment and compound prioritization.
Establishing a Transcriptomic Point of Departure for Acetamide
Our client needed to better understand its mode of action and identify a supported point of departure for risk assessment.
ScitoVation Approach
- Analyzed rat liver gene-expression responses across multiple acetamide doses and exposure durations.
- Applied pathway and gene-set enrichment analyses to investigate mode of action.
- Used transcriptomic benchmark-dose modeling to derive gene- and pathway-level points of departure.
Client Benefit
- Increased confidence with consistent transcriptomic points of departure across multiple analytical approaches.
- Strengthened the assessment through concordance with traditional endpoints.
- Provided a reference point that could support formal human-health risk assessment.
Gene-Expression Biomarkers for Fluorocarbon Compound Prioritization
Our client needed to compare potential liver and endocrine effects across several fluorinated candidate compounds.
ScitoVation Approach
- Assessed cytotoxicity and cell viability in liver and epithelial cell lines.
- Tested compounds at sub-cytotoxic concentrations.
- Used gene-expression biomarkers to evaluate PPARα and ERα activity.
Client Benefit
- Helped identify which compounds showed liver or endocrine activity.
- Enabled rapid, cost-efficient candidate down-selection.
- Helped focus further testing on the most relevant compounds.
How We Determine Mode of Action
ScitoVation uses transcriptomic analysis to identify the genes, pathways, and biological processes associated with a compound’s response.
Combined with targeted validation studies, this can help generate and test mode-of-action hypotheses, explain differences in sensitivity, and guide follow-up development or risk-assessment decisions.
H3: Identifying Mode of Action for Cancer Candidates
Our client needed to understand what was driving sensitivity and resistance to a promising family of cancer compounds.
ScitoVation Approach
- Analyzed cancer cell-line transcriptional data to identify genes associated with sensitivity and resistance.
- Performed whole-transcriptome sequencing and bioinformatic analysis to identify candidate genes and pathways.
- Validated candidate genes in cell-based assays to test whether altering their expression changed sensitivity.
Client Benefit
- Identified a gene strongly associated with sensitivity and resistance.
- Clarified a biological pathway linked to compound efficacy.
- Provided a potential biomarker to support more targeted patient-selection and clinical-development strategies.
Evaluating the Mode of Action of 4-methylimidazole (4-MeI)
Our client wanted to understand the mechanisms behind high-dose 4-MeI exposure being associated with lung tumors in mice, and their relevance to human risk.
ScitoVation Approach
- Integrated mechanistic evidence and high-throughput screening data using a structured weight-of-evidence framework.
- Evaluated potential mechanisms including genotoxicity, cytotoxicity, receptor-mediated effects, and cell proliferation.
- Used transcriptomic data from mouse lung and liver to assess DNA damage response and other mechanistic signals.
Client Benefit
- Strengthened evidence that genotoxicity and cytotoxicity were unlikely to explain the mouse lung tumors.
- Narrowed the range of plausible mechanisms while recognizing that the exact mode of action remained unresolved.
- Provided a more transparent basis for evaluating the relevance of the mouse findings to human risk.
Assessing PPARα-Mediated Mode of Action
We used a published transcriptomic dataset to examine whether DEHP-induced liver responses in mice were dependent on PPARα and what that could mean for interpreting the findings in humans.
ScitoVation Approach
- Analyzed liver gene-expression responses in wild-type and PPARα-null mice following DEHP exposure.
- Compared transcriptomic changes across genotypes to identify PPARα-dependent effects.
- Used gene ontology and transcriptional-profile comparisons to evaluate affected pathways and consistency with PPARα signaling.
Assessment Value
- Characterized the biological pathways altered in the liver response.
- Strengthened evidence for a PPARα-mediated mode of action by showing that key responses were largely absent in PPARα-null mice.
- Provided mechanistic evidence to support evaluation of whether the rodent response is relevant to humans.
How We Assess Biological Similarity for Read-Across and Grouping
ScitoVation uses biological read-across to help assess data-poor compounds by comparing them with more-characterized source compounds.
Transcriptomic data adds biological evidence to structural similarity, helping determine whether compounds can be grouped, read across, or should be assessed separately.
Strengthening Read-Across with Biological Similarity
For a data-poor target compound, structural similarity alone may not provide enough confidence for read-across. We can use transcriptomic similarity to test whether the target behaves biologically like a well-characterized source compound.
ScitoVation Approach
- Select source compounds with relevant toxicity data and a suitable cell model linked to the target tissue.
- Generate RNA-sequencing data across source and target compounds over a concentration range.
- Compare transcriptomic responses to assess biological similarity between compounds.
Assessment Value
- Adds biological evidence to a structure-based read-across argument.
- Helps identify the most appropriate source compound for comparison.
- Strengthens confidence in grouping and supports a more scientifically robust REACH strategy.
Identifying Biological Similarities Across PFAS
ScitoVation re-analyzed human liver spheroid transcriptomic data to determine how PFAS responses differed by chain length and dose.
ScitoVation Approach
- Compared gene-expression responses across 12 PFAS compounds.
- Analyzed differentially expressed genes and Reactome pathway enrichment to identify similarities and differences.
- Assessed transcription-factor binding-site enrichment to explore potential mechanisms.
Assessment Value
- Revealed biological differences between shorter- and longer-chain PFAS.
- Showed dose-dependent changes in pathway enrichment following PFOA exposure.
- Provided biological evidence to support more informed grouping and PFAS risk-assessment decisions.